Breaking News

Financial Report: BMS

By Kristin Brooks | January 24, 2014

Revenues up 6% in the quarter

BMS

4Q Revenues: $4.4 billion (+6%)

4Q Earnings: $735.0 million (-20%)

YTD Revenues: $16.4 billion (-7%)

YTD Earnings: $2.6 billion (+3%)

Comments: U.S. revenues increased 1% to $2.3 billion in the quarter and international revenues increased 11% to $2.2 billion. Yervoy sales grew 23% to $260 million. Onglyza/Kombiglyze sales were $224 million, up 13%. Sprycel sales grew 30% to $365 million, and Orencia sales were up 22% to $397 million. Abilify sales were down 22% to $635 million, due to loss of patent exclusivity. R&D expenses were down 12% to $957 million. In the quarter, the company announced the sale of its diabetes business as part of an effort to evolve its BioPharma strategy to a specialty care model.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks